BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Dec 06, 2023 1:46pm EST
BIOLASE REPORTS THIRD QUARTER FINANCIAL RESULTS; COMPANY BENEFITTING FROM STRATEGIC ACTIONS TAKEN TO STREAMLINE OPERATIONS AND GAIN GREATER OPERATIONAL EFFICIENCIES Nov 09, 2023 4:05pm EST
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol Nov 08, 2023 6:30am EST
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Sep 18, 2023 4:30pm EDT
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants Sep 13, 2023 11:16pm EDT
BIOLASE REPORTS RECORD CONSUMABLE SALES AS TOTAL SECOND QUARTER REVENUE INCREASES 17% YEAR OVER YEAR Aug 10, 2023 4:05pm EDT